Article Text

PDF
Rapid fluorescence in situ hybridisation (FISH) for HER2 (ERBB2) assessment in breast and gastro-oesophageal cancer
  1. Laura J Tafe1,2,3,
  2. Heather B Steinmetz1,
  3. Samantha F Allen1,
  4. Betty J Dokus1,
  5. Gregory J Tsongalis1,2,3
  1. 1Department of Pathology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA
  2. 2Geisel School of Medicine at Dartmouth, Hanover, NH, USA
  3. 3Norris Cotton Cancer Center, Lebanon, NH, USA
  1. Correspondence to Dr Laura J Tafe, Department of Pathology, Dartmouth-Hitchcock Medical Center, One Medical Center, Lebanon, NH 03756, USA; Laura.J.Tafe{at}Hitchcock.org

Abstract

Evaluation of HER2 (ERBB2) gene amplification or protein expression is standard of care in breast (BR) and advanced stage gastro-oesophageal cancers to identify patients eligible for anti-HER2 therapies. Here, we evaluate a rapid fluorescence in situ hybridisation (FISH) technology (HER2 instant quality (IQ) FISH pharmDx Kit) for detection of HER2 in patients with BR and gastro-oesophageal cancer using 30 FFPE samples that had been previously evaluated with the PathVysion HER2 DNA Probe Kit. Cases were scored as positive (HER2:CEN-17 ≥2.0), negative (HER2:CEN-17 <2.0) or equivocal according to the ASCO/CAP 2013 BR cancer guidelines. Ten samples were positive for HER2 amplification while 20 were negative; none were equivocal. The IQ FISH was able to detect low level amplification (HER2:CEN-17 ratio 2.4). The HER2 IQ FISH pharmDx Kit is a FDA approved kit that offers a rapid turnaround time (approximately 3.5 h) and in our laboratory was 100% concordant with prior PathVysion results.

  • BREAST CANCER
  • FISH
  • MOLECULAR PATHOLOGY

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.